Sopherion Therapeutics is a biopharmaceutical company focused on innovating metastatic breast cancer treatment through advanced nanotechnology solutions. Based in Princeton, New Jersey, the company also has offices in Cheshire, Connecticut, Estero, Florida, and Toronto, Canada through its operating subsidiary, Sopherion Therapeutics Canada. The company secured a significant $55.00M Series C investment on 19 February 2009 from Zoticon BioVentures.
Sopherion holds an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., to commercialize Myocet™, a liposome-encapsulated doxorubicin-citrate complex, in the United States and Canada. The company is dedicated to a Phase III global, randomized registration trial for first-line therapy of invasive, metastatic breast cancer, assessing the effectiveness of Myocet™ in combination with Herceptin® and Taxol (Paclitaxel), compared to the current standard of Herceptin® and Taxol alone.
Myocet™, recognized for its reduced cardiotoxicity, has shown promise based on Phase II trials supported by Roche, achieving a 96% response rate and a median progression-free survival of two and a half years for patients with metastatic breast cancer. With the trial reaching full recruitment by March 2009, unblinding was expected by summer 2010, and an NDA submission for full approval planned within six months thereafter. The drug is already registered in Canada and Europe for use in combination with cyclophosphamide in first-line metastatic breast cancer.
